Crystallographic structure (monomer) of bovine xanthine oxidase.
The bounded FAD (red), FeS-cluster (orange), the molybdopterin cofactor with molybdenum (yellow) and salicylate (blue) are indicated.
|PDB structures||RCSB PDB PDBe PDBsum|
|Gene Ontology||AmiGO / EGO|
|Locus||Chr. 2 p23.1|
Xanthine oxidase (XO, sometimes 'XAO') is a form of xanthine oxidoreductase, a type of enzyme that generates reactive oxygen species. These enzymes catalyze the oxidation of hypoxanthine to xanthine and can further catalyze the oxidation of xanthine to uric acid. These enzymes play an important role in the catabolism of purines in some species, including humans.
Xanthine oxidase is defined as an enzyme activity (EC 184.108.40.206). The same protein, which in humans has the HGNC approved gene symbol XDH, can also have xanthine dehydrogenase activity (EC 220.127.116.11). Most of the protein in the liver exists in a form with xanthine dehydrogenase activity, but it can be converted to xanthine oxidase by reversible sulfhydryl oxidation or by irreversible proteolytic modification.
The following chemical reactions are catalyzed by xanthine oxidase:
- hypoxanthine + H2O + O2 <math>\rightleftharpoons</math> xanthine + H2O2
- xanthine + H2O + O2 <math>\rightleftharpoons</math> uric acid + H2O2
- Xanthine oxidase can also act on certain other purines, pterins, and aldehydes. For example, it efficiently converts 1-methylxanthine (a metabolite of caffeine) to 1-methyluric acid, but has little activity on 3-methylxanthine.
- Under some circumstances it can produce superoxide ion RH + H2O + 2 O2 <math>\rightleftharpoons</math> ROH + 2 O2− + 2 H+.
- Hypoxanthin - Hypoxanthine.svg
hypoxanthine (one oxygen atom)
- Xanthin - Xanthine.svg
xanthine (two oxygens)
- Harnsäure Ketoform.svg
uric acid (three oxygens)
Because XO is a superoxide-producing enzyme, with general low specificity, it can be combined with other compounds and enzymes and create reactive oxidants, as well as oxidize other substrates.
Bovine xanthine oxidase (from milk) was originally thought to have a binding site to reduce cytochrome c with, but it has been found that the mechanism to reduce this protein is through XO's superoxide anion byproduct, with competitive inhibition by carbonic anhydrase.
Another reaction catalyzed by xanthine oxidase is the decomposition of S-Nitrosothiols (RSNO), a reactive nitrogen species, to nitric oxide (NO), which reacts with a superoxide anion to form peroxynitrite under aerobic conditions.
XO has also been found to produce the strong one-electron oxidant carbonate radical anion from oxidation with acetaldehyde in the presence of catalase and bicarbonate. It was suggested that the carbonate radical was likely produced in one of the enzyme's redox centers with a peroxymonocarbonate intermediate.
Here is a diagram highlighting the pathways catalyzed by xanthine oxidase.
The protein is large, having a molecular weight of 270 kDa, and has 2 flavin molecules (bound as FAD), 2 molybdenum atoms, and 8 iron atoms bound per enzymatic unit. The molybdenum atoms are contained as molybdopterin cofactors and are the active sites of the enzyme. The iron atoms are part of [2Fe-2S] ferredoxin iron-sulfur clusters and participate in electron transfer reactions.
The active site of XO is composed of a molybdopterin unit with the molybdenum atom also coordinated by terminal oxygen (oxo), sulfur atoms and a terminal hydroxide. In the reaction with xanthine to form uric acid, an oxygen atom is transferred from molybdenum to xanthine, whereby several intermediates are assumed to be involved. The reformation of the active molybdenum center occurs by the addition of water. Like other known molybdenum-containing oxidoreductases, the oxygen atom introduced to the substrate by XO originates from water rather than from dioxygen (O2).
As well, because xanthine oxidase is a metabolic pathway for uric acid formation, the xanthine oxidase inhibitor allopurinol is used in the treatment of gout. Since xanthine oxidase is involved in the metabolism of 6-mercaptopurine, caution should be taken before administering allopurinol and 6-mercaptopurine, or its prodrug azathioprine, in conjunction.
Xanthinuria is a rare genetic disorder where the lack of xanthine oxidase leads to high concentration of xanthine in blood and can cause health problems such as renal failure. There is no specific treatment, sufferers are advised by doctors to avoid foods high in purine and to maintain a high fluid intake. Type I xanthinuria has been traced directly to mutations of the XDH gene which mediates xanthine oxidase activity. Type II xanthinuria may result from a failure of the mechanism which inserts sulfur into the active sites of xanthine oxidase and aldehyde oxidase, a related enzyme with some overlapping activities (such as conversion of allopurinol to oxypurinol).
Inhibition of xanthine oxidase has been proposed as a mechanism for improving cardiovascular health. A study found that patients with chronic obstructive pulmonary disease (COPD) had a decrease in oxidative stress, including glutathione oxidation and lipid peroxidation, when xanthine oxidase was inhibited using allopurinol. Oxidative stress can be caused by hydroxyl free radicals and hydrogen peroxide, both of which are byproducts of XO activity.
Increased concentration of serum uric acid has been under research as an indicator for cardiovascular health factors, and has been used to strongly predict mortality, heart transplant, and more in patients. But it is not clear whether this could be a direct or casual association or link between serum uric acid concentration (and by proxy, xanthine oxidase activity) and cardiovascular health. States of high cell turnover and alcohol ingestion are some of the most prominent cases of high serum uric acid concentrations.
Reactive nitrogen species, such as peroxynitrite that xanthine oxidase can form, have been found to react with DNA, proteins, and cells, causing cellular damage or even toxicity. Reactive nitrogen signaling, coupled with reactive oxygen species, have been found to be a central part of myocardial and vascular function, explaining, why xanthine oxidase is under research to links to cardiovascular health.
Inhibitors of XO include allopurinol, oxypurinol, and phytic acid. It has also been found to be inhibited by flavonoids, including those found in Bougainvillea spectabilis Willd (Nyctaginaceae) leaves (with an IC50 of 7.23 μM), typically used in folk medicine.
- PDB 1FIQ; Enroth C, Eger BT, Okamoto K, Nishino T, Nishino T, Pai EF (September 2000). "Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: structure-based mechanism of conversion". Proc. Natl. Acad. Sci. U.S.A. 97 (20): 10723–8. PMC 27090. PMID 11005854. doi:10.1073/pnas.97.20.10723.
- Ardan T, Kovaceva J, Cejková J (2004). "Comparative histochemical and immunohistochemical study on xanthine oxidoreductase/xanthine oxidase in mammalian corneal epithelium". Acta Histochem 106 (1): 69–75. PMID 15032331. doi:10.1016/j.acthis.2003.08.001.
- Hille R (2005). "Molybdenum-containing hydroxylases". Arch. Biochem. Biophys. 433 (1): 107–16. PMID 15581570. doi:10.1016/j.abb.2004.08.012.
- Harrison R (2002). "Structure and function of xanthine oxidoreductase: where are we now?". Free Radic. Biol. Med. 33 (6): 774–97. PMID 12208366. doi:10.1016/S0891-5849(02)00956-5.
- "KEGG record for EC 18.104.22.168".
- "KEGG record for EC 22.214.171.124".
- "Entrez Gene: XDH xanthine dehydrogenase".
- "*607633 XANTHINE DEHYDROGENASE; XDH".
- D. J. Birkett et al. (1997). "1-Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect" (PDF). Br J Clin Pharmacol 43 (2): 197–200. PMC 2042732. PMID 9131954. doi:10.1046/j.1365-2125.1997.53711.x.
- Bonini, M. G.; Miyamoto, S.; Mascio, P. D.; Augusto, O. (22 September 2004). "Production of the Carbonate Radical Anion during Xanthine Oxidase Turnover in the Presence of Bicarbonate". Journal of Biological Chemistry 279 (50): 51836–51843. doi:10.1074/jbc.M406929200.
- McCord, JM; Fridovich, I (Nov 10, 1968). "The reduction of cytochrome c by milk xanthine oxidase.". The Journal of Biological Chemistry 243 (21): 5753–60. PMID 4972775.
- Trujillo, M. (3 April 1998). "Xanthine Oxidase-mediated Decomposition of S-Nitrosothiols". Journal of Biological Chemistry 273 (14): 7828–7834. doi:10.1074/jbc.273.14.7828.
- Hille R. (2006). "Structure and Function of Xanthine Oxidoreductase". European Journal of Inorganic Chemistry. 2006= (10): 1905–2095. doi:10.1002/ejic.200600087.
- Metz S, Thiel W. (2009). "A Combined QM/MM Study on the Reductive Half-Reaction of Xanthine Oxidase: Substrate Orientation and Mechanism". Journal of the American Chemical Society 131 (41): 14885–158902. PMID 19788181. doi:10.1021/ja9045394.
- "OMIM: Xanthinuria type II".
- Dawson J, Walters M (October 2006). "Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?". British Journal of Clinical Pharmacology 62 (6): 633–44. PMC 1885190. PMID 21894646. doi:10.1111/j.1365-2125.2006.02785.x.
- Heunks, LM; Viña, J; van Herwaarden, CL; Folgering, HT; Gimeno, A; Dekhuijzen, PN (Dec 1999). "Xanthine oxidase is involved in exercise-induced oxidative stress in chronic obstructive pulmonary disease.". The American journal of physiology 277 (6 Pt 2): R1697–704. PMID 10600916.
- Higgins, Peter; Dawson, Jesse; Walters, Matthew (2009). "The Potential for Xanthine Oxidase Inhibition in the Prevention and Treatment of Cardiovascular and Cerebrovascular Disease". Cardiovascular Psychiatry and Neurology 2009: 1–9. doi:10.1155/2009/282059.
- Dawson, J; Quinn, T; Walters, M (2007). "Uric acid reduction: a new paradigm in the management of cardiovascular risk?". Current medicinal chemistry 14 (17): 1879–86. PMID 17627523. doi:10.2174/092986707781058797.
- Zimmet, J. M.; Hare, J. M. (3 October 2006). "Nitroso-Redox Interactions in the Cardiovascular System". Circulation 114 (14): 1531–1544. doi:10.1161/CIRCULATIONAHA.105.605519.
- Cejková J, Ardan T, Filipec M, Midelfart A (2002). "Xanthine oxidoreductase and xanthine oxidase in human cornea". Histol. Histopathol. 17 (3): 755–60. PMID 12168784.
- Pacher P, Nivorozhkin A, Szabó C (March 2006). "Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol". Pharmacol. Rev. 58 (1): 87–114. PMC 2233605. PMID 16507884. doi:10.1124/pr.58.1.6.
- Spector T (January 1988). "Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical". Biochem. Pharmacol. 37 (2): 349–52. PMID 2829916. doi:10.1016/0006-2952(88)90739-3.
- Muraoka S, Miura T (February 2004). "Inhibition of xanthine oxidase by phytic acid and its antioxidative action". Life Sci. 74 (13): 1691–700. PMID 14738912. doi:10.1016/j.lfs.2003.09.040.
- Cos, Paul; Ying, Li; Calomme, Mario; Hu, Jia P.; Cimanga, Kanyanga; Van Poel, Bart; Pieters, Luc; Vlietinck, Arnold J.; Berghe, Dirk Vanden (January 1998). "Structure−Activity Relationship and Classification of Flavonoids as Inhibitors of Xanthine Oxidase and Superoxide Scavengers". Journal of Natural Products 61 (1): 71–76. doi:10.1021/np970237h.
- Chang, WS; Lee, YJ; Lu, FJ; Chiang, HC (Nov–Dec 1993). "Inhibitory effects of flavonoids on xanthine oxidase.". Anticancer research 13 (6A): 2165–70. PMID 8297130.